A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

NCT05441475 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w
DRUG: ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg
DRUG: ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg

Sponsor

Abbisko Therapeutics Co, Ltd